PRA Advances to Become PRA Health Sciences
The Future of Clinical Development Today
PRA, a leading clinical research organization, today announced that it has changed its name to PRA Health Sciences (PRA). The name change to PRA Health Sciences is the culmination of several strategic actions which support and enhance the company’s commitment to the future of clinical development.
Starting over 18 months ago, PRA strategically strengthened its coverage of China and created a joint venture with the leading clinical development firm in China, forming WuXiPRA. PRA then bolstered its capabilities in Russia and Eastern Europe by acquiring ClinStar, the premier provider of CRO services in Russia and Eastern Europe. With the subsequent acquisition of RPS, the pioneer of the Embedded Solutions™ model, PRA enhanced its ability to offer a more comprehensive breadth of services across all segments of the biopharmaceutical industry. At the close of 2013, PRA purchased CRI Lifetree, which augmented its existing Phase I and bioanalytical capabilities, cementing PRA as the most comprehensive, high-end Phase I organization in the world.
"The expansion of our global presence, the growth in our breadth of services, and the deepening of our capabilities we initiated over the last year-and-a-half enable us to better serve our clients," said Colin Shannon, president and CEO, PRA Health Sciences. "This change to our name reflects our historical roots as a scientifically rich company, the breadth and depth of our solutions, and most importantly, our dedication to working with sponsors to bring new treatments to market that will positively impact the lives of patients and their families.”
As one unified company with a broad range of specific expertise, PRA is well-equipped and intently focused on working to improve the lives of patients and providing innovative solutions that will drive the future of clinical development.
In addition to the new name, PRA is introducing a new website more reflective of the company today. This new interactive, website can be experienced at: www.prahs.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
